NCT06847178View on ClinicalTrials.gov

Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
DiabetesType 2 Diabetes
Interventions
DIETARY_SUPPLEMENT

Placebo twice daily in blinding

Administered placebo twice-daily for 12 weeks in blinding

DRUG

Low-dose LC-Z300-01 twice daily in blinding

Administered twice-daily for 12 weeks in blinding

DRUG

High-dose LC-Z300-01 twice daily in blinding

Administered twice-daily for 12 weeks in blinding

DRUG

High-dose LCZ300-1 twice daily in open-label

Administered high-dose LCZ300-1 twice-daily for 12 weeks in open-label

Trial Locations (1)

20003

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER